Fusion protein technologies for biopharmaceuticals : applications and challenges / edited by Stefan R. Schmidt. [electronic resource] Schmidt, Stefan R. Biopharmaceutics. Pharmaceutical biotechnology. Recombinant Fusion Proteins therapeutic use. Drug Carriers. Immunotoxins pharmacokinetics. Immunotoxins therapeutic use. Protein Engineering. Recombinant Fusion Proteins pharmacokinetics. RM301.4 .F87 2013 615.7 23 Includes bibliographical references and index. Print version record and CIP data provided by publisher. The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei. Hoboken, New Jersey : John Wiley & Sons, ©2013. ©2013. 2013 Text 1 online resource. http://onlinelibrary.wiley.com/book/10.1002/9781118354599 eng Fusion protein technologies for biopharmaceuticals. Fusion protein technologies for biopharmaceuticals.